- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00789750
Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
June 23, 2017 updated by: Daiichi Sankyo, Inc.
A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of WELCHOL as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus (T2DM)
The current study investigates colesevelam as add-on therapy to pioglitazone to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with pioglitazone monotherapy or pioglitazone in combination with either metformin or a sulfonylurea.
The study will evaluate if colesevelam add-on to pioglitazone therapy for type 2 diabetes mellitus will be safe, well tolerated, and efficacious.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
562
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
-
Birmingham, Alabama, United States, 35205
-
Birmingham, Alabama, United States, 35216
-
Montgomery, Alabama, United States, 36117
-
Montgomery, Alabama, United States, 36106
-
-
Arizona
-
Green Valley, Arizona, United States, 85614
-
Mesa, Arizona, United States, 85210
-
Phoenix, Arizona, United States, 85050
-
Tempe, Arizona, United States, 85282
-
Tempe, Arizona, United States, 85284
-
-
Arkansas
-
Searcy, Arkansas, United States, 72143
-
-
California
-
Buena Park, California, United States, 90620
-
Burbank, California, United States, 91505
-
Chino, California, United States, 91710
-
Garden Grove, California, United States, 92844
-
Huntington Park, California, United States, 90255
-
La Mirada, California, United States, 90638
-
Lincoln, California, United States, 95648
-
Lomita, California, United States, 90717
-
Los Gatos, California, United States, 95032
-
Modesto, California, United States, 95355
-
San Diego, California, United States, 92161
-
Santa Ana, California, United States, 92701
-
Tustin, California, United States, 92780
-
Walnut Creek, California, United States, 94598
-
-
Florida
-
Coral Gables, Florida, United States, 33134
-
DeLand, Florida, United States, 32720
-
Delray Beach, Florida, United States, 33484
-
Gulf Breeze, Florida, United States, 32561
-
Hialeah, Florida, United States, 33012
-
Jacksonville, Florida, United States, 32223
-
Kissimmee, Florida, United States, 34741
-
Miami, Florida, United States, 33175
-
Miami, Florida, United States, 33169
-
Miami, Florida, United States, 33135
-
Miami, Florida, United States, 33156
-
Miami, Florida, United States, 33183
-
New Port Richey, Florida, United States, 34652
-
Ocala, Florida, United States, 34471
-
Ormond Beach, Florida, United States, 32174
-
Pembroke Pines, Florida, United States, 33026
-
Pembroke Pines, Florida, United States, 33027
-
Pinellas Park, Florida, United States, 33781
-
Sanford, Florida, United States, 32771
-
Tampa, Florida, United States, 33607
-
Vero Beach, Florida, United States, 32960
-
Wellington, Florida, United States, 33449
-
Winter Haven, Florida, United States, 33880
-
Winter Park, Florida, United States, 32792
-
Winter Park, Florida, United States, 32789
-
-
Georgia
-
Columbus, Georgia, United States, 31904
-
Decatur, Georgia, United States, 30035
-
East Point, Georgia, United States, 30344
-
Marietta, Georgia, United States, 30066
-
Roswell, Georgia, United States, 30076
-
Stockbridge, Georgia, United States, 30281
-
Tucker, Georgia, United States, 30084
-
Waycross, Georgia, United States, 31501
-
-
Idaho
-
Nampa, Idaho, United States, 83686
-
-
Illinois
-
Arlington Heights, Illinois, United States, 60004
-
Chicago, Illinois, United States, 60607
-
-
Indiana
-
Bloomington, Indiana, United States, 47403
-
Evansville, Indiana, United States, 47714
-
LaPorte, Indiana, United States, 46350
-
South Bend, Indiana, United States, 46614
-
-
Kentucky
-
Crestview Hills, Kentucky, United States, 41017
-
Paducah, Kentucky, United States, 42003
-
-
Louisiana
-
Lafayette, Louisiana, United States, 70503
-
-
Maryland
-
Prince Frederick, Maryland, United States, 20678
-
Silver Spring, Maryland, United States, 20910
-
-
Massachusetts
-
New Bedford, Massachusetts, United States, 02740
-
-
Michigan
-
Southfield, Michigan, United States, 48034
-
-
Minnesota
-
Brooklyn Center, Minnesota, United States, 55430
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
-
Port Gibson, Mississippi, United States, 39150
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
-
Saint Louis, Missouri, United States, 63141
-
-
Montana
-
Billings, Montana, United States, 59101
-
-
Nevada
-
Las Vegas, Nevada, United States, 89123
-
-
New Jersey
-
Belvidere, New Jersey, United States, 07823
-
Berlin, New Jersey, United States, 08009
-
Clifton, New Jersey, United States, 07013
-
Lumberton, New Jersey, United States, 08048
-
Mine Hill, New Jersey, United States, 07803
-
-
New York
-
New Windsor, New York, United States, 12553
-
North Massapequa, New York, United States, 11758
-
Tonawanda, New York, United States, 14150
-
West Seneca, New York, United States, 14224
-
-
North Carolina
-
Lexington, North Carolina, United States, 27293
-
Statesville, North Carolina, United States, 28625
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
-
Cincinnati, Ohio, United States, 45227
-
Cincinnati, Ohio, United States, 45245
-
Cleveland, Ohio, United States, 44122
-
Columbus, Ohio, United States, 43213
-
Cuyahoga Falls, Ohio, United States, 44223
-
Marion, Ohio, United States, 43302
-
Shaker Heights, Ohio, United States, 44120
-
Stow, Ohio, United States, 44224
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73103
-
Oklahoma City, Oklahoma, United States, 73132
-
Oklahoma City, Oklahoma, United States, 73159
-
-
Oregon
-
Portland, Oregon, United States, 97220
-
-
Pennsylvania
-
Harrisburg, Pennsylvania, United States, 17112
-
Jersey Shore, Pennsylvania, United States, 17740
-
Philadelphia, Pennsylvania, United States, 19140
-
Philadelphia, Pennsylvania, United States, 19153
-
Upper Saint Clair, Pennsylvania, United States, 15241
-
-
South Carolina
-
Charleston, South Carolina, United States, 29414
-
Charleston, South Carolina, United States, 29412
-
Columbia, South Carolina, United States, 29201
-
Greer, South Carolina, United States, 29651
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
-
Jackson, Tennessee, United States, 38305
-
Murfreesboro, Tennessee, United States, 37130
-
New Tazewell, Tennessee, United States, 37825
-
-
Texas
-
Arlington, Texas, United States, 76012
-
Dallas, Texas, United States, 75231
-
Dallas, Texas, United States, 75230
-
Dallas, Texas, United States, 75235
-
Fort Worth, Texas, United States, 76117
-
Grand Prairie, Texas, United States, 75052
-
Houston, Texas, United States, 77074
-
Houston, Texas, United States, 77008
-
Houston, Texas, United States, 77081
-
Houston, Texas, United States, 77083
-
San Antonio, Texas, United States, 78229
-
San Antonio, Texas, United States, 78209
-
Sugar Land, Texas, United States, 77479
-
Sugar Land, Texas, United States, 77478
-
Tomball, Texas, United States, 77375
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
-
Salt Lake City, Utah, United States, 84102
-
-
Virginia
-
Alexandria, Virginia, United States, 22304
-
Danville, Virginia, United States, 24541
-
Manassas, Virginia, United States, 20110
-
Richmond, Virginia, United States, 23225
-
Salem, Virginia, United States, 24153
-
Suffolk, Virginia, United States, 23435
-
-
Washington
-
Lakewood, Washington, United States, 98499
-
-
Wisconsin
-
Kenosha, Wisconsin, United States, 53142
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of Type 2 diabetes mellitus
- Inadequate glycemic control on a stable dose (at least 2 months prior to screening) of pioglitazone at 30 or 45 mg/day, with or without one or two other oral antidiabetic medications [metformin or a sulfonylurea, or dipeptidyl peptidase (DPP-IV) inhibitor]
- Hemoglobin A1c (HbA1c) >= 7.5% and =< 9.5% at screening
- Fasting plasma glucose =<240 mg/dL at randomization (Week 0/Day 1).
- Male or female >= 18 years of age.
- Women of childbearing potential must be using an adequate method of contraception as detailed per-protocol
- Fasting C-peptide level >0.5 ng/mL at screening
- Clinically stable in regards to medical conditions other than type 2 diabetes
- Concomitant medications are at stable doses for at least 30 days prior to enrollment, and are not anticipated to need adjustment during the study period
Exclusion Criteria:
- History of Type 1 diabetes and/or history of ketoacidosis
- History of bowel obstruction
- History of hypertriglyceridemia-induced pancreatitis
- Fasting serum triglyceride concentration >500 mg/dL
- History of dysphagia, swallowing disorders, gastroparesis, other gastrointestinal motility disorders, major gastrointestinal surgery
- History of insulin use >= 2 weeks duration during the previous 3 months or a total of >2 months insulin therapy at any time prior to screening
- Treatment with bile acid sequestrants, including colesevelam within 3 months prior to screening
- Female subject who is pregnant or breastfeeding
- History of unstable angina, myocardial infarction, cerebrovascular accident, transient ischemic attack, or any revascularization within 6 months prior to screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Colesevelam
Participants receive six colesevelam tablets (3.8 grams/day) in addition to pioglitazone-based therapy (30 mg or 45 mg)
|
Colesevelam 625 mg tablets
Other Names:
30 mg or 45 mg pioglitazone therapy
Other Names:
|
|
Placebo Comparator: Placebo
Participants receive six placebo tablets in addition to pioglitazone-based therapy (30 mg or 45 mg)
|
30 mg or 45 mg pioglitazone therapy
Other Names:
Placebo tablets appearing to be colesevelam
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24
Time Frame: Baseline, Week 24
|
Baseline, Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in HbA1c at Week 4
Time Frame: Baseline, Week 4
|
Baseline, Week 4
|
|
|
Change From Baseline in HbA1c at Week 8
Time Frame: Baseline, Week 8
|
Baseline, Week 8
|
|
|
Change From Baseline in HbA1c at Week 16
Time Frame: Baseline, Week 16
|
Baseline, Week 16
|
|
|
Number of Participants Achieving an HbA1c Goal of <7.0%
Time Frame: Week 24
|
Week 24
|
|
|
Change From Baseline in Fasting Plasma Glucose (FPG)
Time Frame: Baseline, Week 24
|
In this study a reduction in FPG of at least 30 mg/dL is considered glycemic response.
|
Baseline, Week 24
|
|
Number of Participants With a Decrease of >= 0.7 Percent in HbA1c
Time Frame: Week 24
|
Week 24
|
|
|
Number of Participants With a Decrease of >= 0.5 Percent in HbA1c
Time Frame: Week 24
|
Week 24
|
|
|
Number of Participants With a Reduction in FPG of >= 30 mg/dL
Time Frame: Week 24
|
Week 24
|
|
|
Percent Change From Baseline in Total Cholesterol (TC)
Time Frame: Baseline, Week 24
|
TC is measured in milligrams per deciliter (mg/dL)
|
Baseline, Week 24
|
|
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Time Frame: Baseline, Week 24
|
LDL-C is measured in mg/dL
|
Baseline, Week 24
|
|
Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)
Time Frame: Baseline, Week 24
|
HDL-C is measured in mg/dL
|
Baseline, Week 24
|
|
Percent Change From Baseline in Non-HDL-C
Time Frame: Baseline, Week 24
|
Non-HDL-C is measured in mg/dL
|
Baseline, Week 24
|
|
Percent Change From Baseline in Triglycerides (TG)
Time Frame: Baseline, Week 24
|
TG are measured in mg/dL
|
Baseline, Week 24
|
|
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-I)
Time Frame: Baseline, Week 24
|
Apo A-1 is measured in mg/dL
|
Baseline, Week 24
|
|
Percent Change From Baseline in Apolipoprotein B (Apo B)
Time Frame: Baseline, Week 24
|
Apo B is measured in mg/dL
|
Baseline, Week 24
|
|
Change From Baseline in Fasting Insulin Levels
Time Frame: Baseline, Week 24
|
Baseline, Week 24
|
|
|
Change From Baseline in Fasting C-peptide
Time Frame: Baseline, Week 24
|
Baseline, Week 24
|
|
|
Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Time Frame: Baseline, Week 24
|
HOMA-IR is a calculation of fasting insulin and fasting glucose that shows the level of insulin resistance.
Lower numbers are better.
|
Baseline, Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2009
Primary Completion (Actual)
July 1, 2012
Study Completion (Actual)
July 1, 2012
Study Registration Dates
First Submitted
November 10, 2008
First Submitted That Met QC Criteria
November 10, 2008
First Posted (Estimate)
November 13, 2008
Study Record Updates
Last Update Posted (Actual)
June 26, 2017
Last Update Submitted That Met QC Criteria
June 23, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Pioglitazone
- Colesevelam Hydrochloride
Other Study ID Numbers
- WEL-A-U306
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.